Linked Life Data

310813

Source:http://linkedlifedata.com/resource/pubmed/id/310813

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1979-4-25
pubmed:abstractText
Eighteen patients with advanced cancer were given subcutaneous injections of pooled dialyzable transfer factor (TFd) from normal donors for periods of from 9 days to 6.5 months. Minor tumor regression was observed in only two patients, an effect of no therapeutic significance. However, treatment with TFd was associated with at least a temporary increase in delayed hypersensitivity reactions in 12 of 17 patients tested, including four patients who became responsive to 2,4-dinitrochlorobenzene. In general, in vitro tests of immune function were not changed after treatment with TFd except for levels of C1q, and/or C3, which were increased in 6 of 10 patients tested. We conclude that TFd may augment delayed hypersensitivity in patients with advanced cancer, and that its effects are, at least in part, immunologically nonsepcific.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0021-2180
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1026-38
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1978
pubmed:articleTitle
Effects of transfer factor in patients with advanced cancer.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.